Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Meanwhile, Novartis could be looking at another label expansion opportunity with Pluvicto. On Thursday, the company revealed that the phase 3 PSMAddition trial in metastatic hormone-sensitive ...

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant Novartis AG ...

For Novartis, investing in the infrastructure to produce and distribute radiopharmaceuticals would be worthwhile for Pluvicto and Lutathera alone, Bulto said. But it's even more attractive because ...

Novartis received approval from the Food and Drug Administration to produce its Pluvicto radioligand therapy at its new manufacturing facility in Indianapolis, expanding capacity to meet growing ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Novartis is expanding U.S. production of cancer drug Pluvicto, a build-up that will help the therapy see blockbuster sales. The Swiss drugmaker said Friday it won Food and Drug Administration ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...